PLANTATION, Fla., May 22 /PRNewswire-FirstCall/ -- In conjunction with
its strategy to seek broader regulatory approvals throughout Europe for
Multiferon(R) (multi-subtype, natural human alpha interferon) as a
first-line adjuvant treatment of high-risk malignant melanoma, Viragen,
Inc. (Amex: VRA) and Viragen International, Inc. (OTC Bulletin Board: VGNI)
today announced that the Companies will exhibit at the 6th International
Conference on the Adjuvant Therapy of Malignant Melanoma in Stockholm,
Sweden on June 15- 17. Multiferon(R) was approved for sale in Sweden in
February of this year for the first-line adjuvant treatment of high-risk
malignant melanoma following dacarbazine (DTIC) after surgical removal of
tumors.
Event details are as follows:
* 6th Annual International Conference on the Adjuvant Therapy of
Malignant Melanoma, June 15-17, 2006, Hotel Rival, Stockholm, Sweden For
more information: http://www.congrex.com/melanoma
"The adjuvant treatment of malignant melanoma is inconsistent
throughout the EU. In most countries where therapy is approved, the
regimens include expensive, difficult-to-tolerate therapies that often
offer only marginal improvements in survival rates for high-risk category
patients," stated Orjan Norberg, Managing Director of ViraNative AB, a
Viragen International subsidiary that manufactures Multiferon(R) in Umea,
Sweden. "We are committed to raising public awareness of the increasing
global incidence of melanoma and to make physicians and patients aware that
our Multiferon(R) regimen offers a safe and effective treatment option with
a significant reduction in total treatment time and cost."
To view the Swedish Multiferon(R) advertisement, please visit:
http://www.viragen.com/images/press/multiferon%20ad%20web.pdf
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a
biotechnology company engaged in the research, development, manufacture and
commercialization of pharmaceutical proteins for the treatment of viral
diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
subtype, natural human alpha interferon) targeting a broad range of
infectious and malignant diseases; and humanized monoclonal antibodies
targeting specific antigens over-expressed on many types of cancers. We are
also pioneering the development of Avian Transgenic Technology, with the
renowned Roslin Institute, as a revolutionary manufacturing platform for
the large-scale, efficient and economical production of human therapeutic
proteins and antibodies.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements
that can be identified by such terminology such as "believes," "expects,"
"potential," "plans," "suggests," "may," "should," "could," "intends," or
similar expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally;
the Company's ability to obtain or maintain patent and other proprietary
intellectual property protection; and competition in general.
Forward-looking statements speak only as to the date they are made. The
Company does not undertake to update forward-looking statements to reflect
circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.; Viragen International, Inc.
 back to top
Related links:
http://www.viragen.com
http://www.congrex.com/melanoma
http://www.viragen.com/images/press/multiferon%20ad%20web.pdf/
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
